February 11, 2008
Otsuka Otsuka has one blockbuster on the global market, the anti-schizophrenic Abilify (aripiprazole) for controlling bipolar disturbances with annual sales of US$1.36 billion with BMS in 2006. Its injectable formulation for bipolar disturbances and oral tablets for add-on therapy for...read more